stockrowJaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024.
- Revenue
- −58.9%
- EPS
- +95.6%
- Free cash flow
- +13.8%
- Total debt
- −83.9%
Quarter to June 2026, against a year earlier
Follow JAGX
Alert me
Jaguar Animal Health, Inc. (JAGX) EV/Sales
As of 6 November 2026, Jaguar Animal Health, Inc. (JAGX) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −0.1× (November 2026) to 19,094,185,096,670× (January 2016) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | (53.01%) |
| FY2024 | 2.4× | (10.11%) |
| FY2023 | 2.7× | (100.00%) |
| FY2022 | 570,135× | (93.25%) |
| FY2021 | 8,447,888× | (94.11%) |
| FY2020 | 143,369,723× | 17.49% |
| FY2019 | 122,027,887× | (9.52%) |
| FY2018 | 134,870,296× | (99.26%) |
| FY2017 | 18,282,754,420× | (99.81%) |
| FY2016 | 9,661,624,906,853× | (3.07%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.1× | — |
| Mar 2026 | 0.3× | (77.69%) |
| Dec 2025 | 1.1× | 60.65% |
| Sep 2025 | 0.7× | (30.50%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | −2.8× |
| JAGX Jaguar Animal Health, Inc. | −0.1× |
| MTNB Matinas Biopharma Holdings, Inc. compare | −0.1× |
| BBLG Bone Biologics Corp. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | 0.3× |
| VBIO Valion Bio, Inc. compare | 11.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)